Tags

Type your tag names separated by a space and hit enter

Potential benefits from currently available three pneumococcal vaccines for children--population-based evaluation.
Klin Padiatr. 2011 Mar; 223(2):61-4.KP

Abstract

BACKGROUND

Currently there are 3 pneumococcal vaccines available in Germany. The aim of this study is to evaluate the potential of the three currently available pneumococcal vaccines to reduce the burden of invasive pneumococcal disease in children.

SUBJECTS

Children younger than 16 years who have been hospitalized because of IPD between July 2007 and June 2009 in a German pediatric hospitals.

METHOD

Surveillance of IPD in German pediatric hospitals and laboratories serving these hospitals. The case definition is isolation of Streptococcus pneumoniae from any normally sterile body site. The actual number of IPD cases is based on the capture recapture method combining information from both reporting systems.

RESULTS

In the study period an estimated yearly number of 164 IPD cases occurred among children younger than 2 years compared to 144 and 116 cases among children aged 2-4 years and 5-15 years. Among children under 2 years of age, 69 cases were caused by serotypes covered by PCV10 compared to 103 cases potentially preventable by PCV13. Among children aged 2-4 years 94 IPD cases were caused by serotypes covered by PCV13 compared to 108 cases covered by PPV23.

CONCLUSION

The newly available pneumococcal conjugate vaccines with better serotype coverage have the potential to further reduce IPD burden in Germany. The additional benefit of vaccination of children aged 2-4 years at high risk for pneumococcal infections with PPV23 is questionable.

Authors+Show Affiliations

Institute of Social Pediatrics and Adolescent Medicine, Ludwig-Maximilian-University of Munich, Germany. simon.rueckinger@med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21271500

Citation

Rückinger, S, et al. "Potential Benefits From Currently Available Three Pneumococcal Vaccines for Children--population-based Evaluation." Klinische Padiatrie, vol. 223, no. 2, 2011, pp. 61-4.
Rückinger S, van der Linden M, Siedler A, et al. Potential benefits from currently available three pneumococcal vaccines for children--population-based evaluation. Klin Padiatr. 2011;223(2):61-4.
Rückinger, S., van der Linden, M., Siedler, A., & von Kries, R. (2011). Potential benefits from currently available three pneumococcal vaccines for children--population-based evaluation. Klinische Padiatrie, 223(2), 61-4. https://doi.org/10.1055/s-0030-1268465
Rückinger S, et al. Potential Benefits From Currently Available Three Pneumococcal Vaccines for Children--population-based Evaluation. Klin Padiatr. 2011;223(2):61-4. PubMed PMID: 21271500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential benefits from currently available three pneumococcal vaccines for children--population-based evaluation. AU - Rückinger,S, AU - van der Linden,M, AU - Siedler,A, AU - von Kries,R, Y1 - 2011/01/26/ PY - 2011/1/29/entrez PY - 2011/1/29/pubmed PY - 2011/8/16/medline SP - 61 EP - 4 JF - Klinische Padiatrie JO - Klin Padiatr VL - 223 IS - 2 N2 - BACKGROUND: Currently there are 3 pneumococcal vaccines available in Germany. The aim of this study is to evaluate the potential of the three currently available pneumococcal vaccines to reduce the burden of invasive pneumococcal disease in children. SUBJECTS: Children younger than 16 years who have been hospitalized because of IPD between July 2007 and June 2009 in a German pediatric hospitals. METHOD: Surveillance of IPD in German pediatric hospitals and laboratories serving these hospitals. The case definition is isolation of Streptococcus pneumoniae from any normally sterile body site. The actual number of IPD cases is based on the capture recapture method combining information from both reporting systems. RESULTS: In the study period an estimated yearly number of 164 IPD cases occurred among children younger than 2 years compared to 144 and 116 cases among children aged 2-4 years and 5-15 years. Among children under 2 years of age, 69 cases were caused by serotypes covered by PCV10 compared to 103 cases potentially preventable by PCV13. Among children aged 2-4 years 94 IPD cases were caused by serotypes covered by PCV13 compared to 108 cases covered by PPV23. CONCLUSION: The newly available pneumococcal conjugate vaccines with better serotype coverage have the potential to further reduce IPD burden in Germany. The additional benefit of vaccination of children aged 2-4 years at high risk for pneumococcal infections with PPV23 is questionable. SN - 1439-3824 UR - https://www.unboundmedicine.com/medline/citation/21271500/Potential_benefits_from_currently_available_three_pneumococcal_vaccines_for_children__population_based_evaluation_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0030-1268465 DB - PRIME DP - Unbound Medicine ER -